针对帕金森病的预防,重定位二基酸酶-4抑制剂:一种药物向的门德尔随机化研究
Joo-Yeon Lee1, Don Gueu Park2, Joohon Sung3
1Institute of Health and Environments, Seoul National University, Seoul, 08826, South Korea.
概括
双基化酶-4抑制剂 (DPP-4Is) 可能减少帕金森氏症.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 遗传学 是一个遗传学.
背景情况:
- 帕金森病 (PD) 缺乏有效的疾病修饰治疗方法.
- 用于糖尿病的二乙酶-4抑制剂 (DPP-4Is) 显示出潜在的神经保护作用.
- 药物再利用提供了一种寻找新PD疗法的策略.
研究的目的:
- 评估重新利用DPP-4I来降低PD风险的潜力.
- 使用孟德尔随机化 (MR) 方法研究DPP-4Is对PD风险的性别特异性影响.
- 探索潜在的调解因素和共同的遗传变异.
主要方法:
- 使用基因表达 (IVeQTL) 和蛋白质定量特征位置 (IVpQTL) 数据进行双样本药物标孟德尔随机化 (MR).
- 利用大规模的PD全基因组关联研究 (GWAS) 与性别分层分析.
- 进行过敏感性分析,调解和局部化分析.
主要成果:
- 基因代理的DPP-4抑制与PD风险降低有关 (IVeQTL:或1.78;IVpQTL:或1.21).
- 在男性 (IVeQTL:OR 2.25; IVpQTL:OR 1.35) 中,有益效应更为明显,而在女性中则不显著.
- 糖尿病并没有调解这种关联;局部化表明主要在男性中共享的变体.
结论:
- DPP-4I显示出降低PD风险的潜力,特别是在男性中.
- 这支持DPP-4Is作为PD预防的潜在策略的重新使用.
- 研究结果突出了针对神经退行性疾病的药物向MR研究中的性别特异性影响.
相关概念视频
01:23Dipeptidyl Peptidase 4 Inhibitors
547
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
547
01:24Parkinson's Disease: Treatment
933
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
933
01:24Glucagon-like Receptor Agonists
816
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
816
01:21EPS and iPS Cells in Disease Research
3.3K
Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...
3.3K
01:15Parkinson's Disease: Overview
1.7K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.7K